 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 80–90% |
| Protein binding | 5–7% |
| Metabolism | Hepaticdeacetylation Minor involvement ofCYP2D6 andCYP2A6 |
| Eliminationhalf-life | 5–7 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H28N2O4 |
| Molar mass | 348.443 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Roxatidine acetate is a specific and competitivehistamine H2 receptor antagonist drug that is used to treatgastric ulcers,Zollinger–Ellison syndrome,erosive esophagitis,gastro-oesophageal reflux disease, andgastritis.[1][2]
Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressinggastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[1]
It was patented in 1979 and approved for medical use in 1986.[3] It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece, and South Africa.[2]
The reductive amination betweenpiperidine (1) and3-hydroxybenzaldehyde (2) gives 3-(1-piperidinylmethyl)phenol (3).Williamson ether synthesis withN-(3-bromopropyl)phthalimide (4) gives the intermediate5.Deprotection withhydrazine yields (3-(1-piperidinylmethyl)phenoxy)propylamine (6). Heating withglycolic acid (7) provides roxatidine (8) which is then converted to its acetate ester, roxatidine acetate (9), by acetylation withacetic anhydride.
